GLP-1RA Improve Liver Outcomes in Patients With Alcohol Use: AJG, March 2026

Introduction

Harmful alcohol use remains a major cause of chronic liver disease, cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality worldwide. Despite advances in hepatology care, effective pharmacologic strategies that simultaneously address alcohol use behaviour and liver disease progression are limited. Recent anecdotal observations have suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—commonly used for diabetes and obesity—may reduce alcohol craving and consumption. However, their potential impact on liver-related outcomes and mortality in individuals with harmful alcohol use has not been well studied.

Summary

In this target trial emulation study using US Veterans' electronic health records, investigators evaluated the association between GLP-1 RA use and liver outcomes in patients with harmful alcohol use. A total of 8,040 GLP-1 RA initiators with positive AUDIT-C scores were propensity-score matched with 8,040 nonusers and followed longitudinally.

GLP-1 RA therapy was associated with a 30% lower risk of composite liver-related outcomes (hepatic decompensation, hepatocellular carcinoma, liver-related death, or all-cause mortality) (adjusted HR 0.70). Importantly, all-cause mortality was reduced by 57% (adjusted HR 0.43). Among semaglutide users, higher weekly doses were linked with even greater reductions in liver outcomes and mortality. Additionally, GLP-1 RA users showed lower odds of continued harmful alcohol use during follow-up (adjusted OR 0.75).

Conclusion

GLP-1 receptor agonists may offer dual benefits in patients with harmful alcohol use—reducing alcohol consumption and improving liver-related outcomes and survival. These findings suggest a potential novel therapeutic role for GLP-1 RAs in alcohol-associated liver disease, although randomized clinical trials are needed for confirmation.